Sei Investments Co. Raises Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Sei Investments Co. lifted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 96,857 shares of the medical instruments supplier's stock after buying an additional 8,494 shares during the period. Sei Investments Co. owned approximately 0.43% of LeMaitre Vascular worth $8,924,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Copeland Capital Management LLC boosted its stake in shares of LeMaitre Vascular by 0.7% during the fourth quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock valued at $107,990,000 after purchasing an additional 8,623 shares during the period. State Street Corp boosted its position in LeMaitre Vascular by 3.6% during the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock valued at $76,363,000 after buying an additional 28,525 shares during the period. Congress Asset Management Co. grew its holdings in LeMaitre Vascular by 1.8% in the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock worth $66,555,000 after acquiring an additional 13,009 shares during the last quarter. Geode Capital Management LLC increased its position in shares of LeMaitre Vascular by 4.5% in the third quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier's stock valued at $50,403,000 after acquiring an additional 23,443 shares during the period. Finally, DF Dent & Co. Inc. raised its stake in shares of LeMaitre Vascular by 26.2% during the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier's stock valued at $24,037,000 after acquiring an additional 53,797 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LMAT. Lake Street Capital increased their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, StockNews.com lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $95.25.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.79% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of LMAT stock traded down $4.78 during trading hours on Thursday, reaching $81.84. The company had a trading volume of 299,926 shares, compared to its average volume of 155,564. The business has a fifty day moving average price of $91.96 and a 200-day moving average price of $94.22. LeMaitre Vascular, Inc. has a one year low of $62.39 and a one year high of $109.58. The firm has a market cap of $1.85 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts' consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.98%. The ex-dividend date was Thursday, March 13th. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's payout ratio is currently 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.